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It is a key issue in immunology to understand how the
immune system discriminates between self- and nonself, in-
hibiting autoimmune responses but allowing the host to
mount immune responses against invading microbes (1–3).
This is due to the fact that once antigen-specific lympho-
cytes are activated in adaptive immune responses, they ex-
hibit essentially the same effector activity whether they re-
spond to a microbe or to a self-constituent. That is, once
aberrant immune responses (e.g., autoimmune, immuno-
pathologic, or allergic responses) are triggered, serious
damage to the host may ensue because of the power of po-
tent effector activity, high antigen specificity, and immu-
nologic memory of adaptive immunity. There is now accu-
mulating evidence in humans and animals that the normal
 
immune system harbors naturally arising CD4
 
  
 
regulatory
 
T (T
 
R
 
) cells, which play key roles in controlling such ab-
errant immune responses (4, 5).
The majority, if not all, of naturally occurring CD4
 
  
 
T
 
R
 
cells constitutively express CD25 (IL-2 receptor 
 
  
 
chain)
in the physiologic state (4, 5). At least some of them are
produced by the normal thymus as a functionally mature T
cell subpopulation with a broad TCR repertoire recogniz-
ing self- and nonself antigens (4). They are engaged in the
maintenance of immunologic self-tolerance by actively
suppressing the activation and expansion of self-reactive
lymphocytes that may cause autoimmune disease. This is
illustrated by the finding that the removal of CD25
 
  
 
CD4
 
 
 
T cells, which constitute 5–10% of peripheral CD4
 
  
 
T
cells in mice, leads to spontaneous development of various
autoimmune diseases in otherwise normal mice. Reconsti-
tution of the depleted population prevents the autoimmu-
 
nity (6). The removal of this population also triggers ex-
cessive or misdirected immune responses to microbial
antigens, causing immunopathology. For example, deple-
tion of T
 
R 
 
cells elicits inflammatory bowel disease in mice
due to hyperreaction of the remaining T cells to commen-
sal bacteria in the intestine (7). Their depletion similarly
precipitates severe pneumonitis in mice that are opportu-
 
nistically infected with 
 
Pneumocystis carinii
 
 (8). In contrast,
such treatments can enhance protective immune responses
against invading microbes including bacteria, viruses,
fungi, and intracellular parasites, leading to their eradica-
tion from the host (9–13). Thus, naturally occurring
CD25
 
  
 
CD4
 
  
 
T
 
R 
 
cells not only inhibit immune responses
against self-antigens but also hamper or suppress those
against microbes invading or cohabiting with the host.
This raises a critical question: how do CD25
 
  
 
CD4
 
  
 
T
 
R
 
cells manage to suppress autoimmune responses or excessive
antimicrobial immune responses causing immunopathol-
ogy, but allow protective responses against invading
pathogenic microbes?
 
Expression of Toll-like Receptors (TLRs) on CD25
 
  
 
CD4
 
 
 
T
 
R 
 
Cells.
 
A report by Caramalho et al. (14) in this issue
provides some clues to the above question. It shows that
 
naturally arising CD25
 
  
 
CD4
 
  
 
T
 
R 
 
cells in normal mice se-
lectively express several members of the TLR family and
that stimulation of CD25
 
  
 
CD4
 
  
 
T
 
R 
 
cells through TLRs
can expand them and strengthen their suppressive activity.
 
TLRs, homologues of Toll receptor in 
 
Drosophila
 
, are germ-
line-encoded receptors that recognize pathogen-associ-
ated molecular patterns shared by large groups of microbes
or certain endogenous molecules released during inflamma-
tion (15, 16). The ten members of TLR (TLRs 1–10) that
have been so far reported in humans and mice respond to
different ligands. For example, TLR4 recognizes LPS, a
major component of gram-negative bacteria, and is also
implicated in the recognition of heat shock protein (HSP)
60/70 and extracellular matrix breakdown products de-
rived from necrotic tissue in inflammation (15, 16). Differ-
ent classes of TLRs are differentially expressed on immune
cells such as dendritic cells (DCs), macrophages, B cells,
 
and certain 
 
   
 
T cells (15–17). Caramalho et al. (14) show
that CD25
 
  
 
CD4
 
  
 
T cells in normal naive mice selectively
express TLR4, 5, 7, and 8 (TLR1, 2, and 6 appear to be
more broadly expressed on CD4
 
  
 
T cells, and not con-
fined to CD25
 
  
 
CD4
 
  
 
T cells). In vitro stimulation of
CD25
 
  
 
CD4
 
  
 
T cells with LPS elicits their proliferation,
prolongs their survival, and augments their in vitro sup-
pressive activity even in the absence of APCs, indicating
that LPS directly acts on TLR4 molecules expressed by T
 
R
 
cells. On the other hand, it is known that LPS stimulation
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of DCs triggers their maturation, leading to enhanced an-
tigen processing, increased MHC expression, migration to
the lymph nodes, production of proinflammatory cyto-
kines and chemokines, and most importantly, induction of
costimulatory molecules such as CD80 and CD86 (18).
Thus, stimulation of TLRs have different effects on im-
mune responses, i.e., one is to trigger DC maturation and
augment T cell–mediated adaptive immunity and another
is to activate endogenous CD25
 
  
 
CD4
 
  
 
T
 
R 
 
cells and
thereby down-regulate immune responses. Although these
effects are apparently conflicting, it is of note that the con-
centration of LPS required for evoking the proliferation of
T
 
R 
 
cells and augmenting their suppressive activity in vitro
is several orders of magnitude higher than the concentra-
tion required for in vitro activation of DCs (14, 18). It is
therefore likely that upon gram-negative bacterial infec-
tion, LPS stimulation of TLRs on DCs will trigger matu-
ration of DCs, thereby evoking the activation, expansion,
and differentiation of microbe-specific naive T cells to ef-
fector T cells. If so large an amount of LPS is produced,
T
 
R 
 
cells activated by LPS through TLRs may augment
their suppressive activity and thereby prevent local or sys-
temic immunopathology (such as septic shock) due to the
production of large amounts of proinflammatory cytokines
(such as TNF
 
  
 
and IL-1) by macrophages. IL-10 pro-
duced by activated T
 
R 
 
cells may suppress activation of
macrophages and their cytokine production (12). Further-
more, IL-2 in the local milieu and TCR stimulation by
microbial antigens may synergistically augment the sup-
pressive activity of TLR-stimulated T
 
R 
 
cells (14). The T
 
R
 
cells thus activated may also suppress the activation and
expansion of self-reactive T cells that are recruited to the
infection site where APCs present self-peptides derived
from damaged tissues.
 
Tuning of the Intensity of T Cell–mediated Immunoregula-
tion.
 
In addition to TLRs, other molecules expressed by
endogenous CD25
 
  
 
CD4
 
  
 
T
 
R 
 
cells transduce signals to T
 
R
 
cells upon interacting with particular ligands and thereby
contribute to tuning the degree of their expansion and
suppressive activity. Accessory molecules on T
 
R 
 
cells, for
example, interact with costimulatory molecules on APCs,
DCs in particular, and thereby confer signals augmenting
or attenuating the activation state of T
 
R 
 
cells with conse-
quences for their suppressive activity. Unlike other T cells,
CD25
 
  
 
CD4
 
  
 
T
 
R 
 
cells constitutively express CTLA-4
(CD152) and this appears to be required for their activa-
tion because specific blockade of the interaction between
CTLA-4 on CD25
 
  
 
CD4
 
  
 
T
 
R 
 
cells and CD80/CD86 on
APCs abrogates suppression (4). In contrast, active signal-
ing through CD28, along with TCR stimulation, neutral-
izes suppression (4). CTLA-4 has much higher (
 
 
 
100-
fold) affinity for CD80/CD86 molecules than CD28 (19).
Based on these findings, the following scenario can be en-
visaged for the roles of T
 
R 
 
cells in controlling immune re-
sponses in the normal state or upon infection (Fig. 1). In
the absence of infection, APCs express basal levels of
CD80/CD86 and a low level of class II MHC binding self-
peptides. CD25
 
  
 
CD4
 
  
 
T
 
R 
 
cells with self-specificity might
 
be activated by recognizing self-peptides (e.g., derived
from apoptotic cells) and receiving a signal through
CTLA-4, but not through CD28, and thereby suppress au-
toreactive T cells. Upon infection, APCs are activated and
increase their expression of CD80/CD86 and class II
MHC molecules bound to microbe-derived peptides.
CD25
 
  
 
CD4
 
  
 
T
 
R 
 
cells recognizing the peptides will re-
ceive a signal through CD28 in addition to CTLA-4,
lessen their suppressive activity, and allow the activation/
expansion of effector T cells capable of eliminating mi-
crobes. IL-2 from responding effector T cells and a signal
through glucocorticoid-induced TNF receptor–related
gene (GITR) also act to attenuate the suppressive activity
of T
 
R 
 
cells in synergy with the signal through CD28 (Fig.
1 and see below; reference 20). With the elimination of
microbes, together with a reduction of the APCs present-
ing the microbial peptides and a decrease of CD80/CD86
expression, T
 
R 
 
cells revert to their original state and reac-
quire the basal regulatory activity.
CD25
 
  
 
CD4
 
  
 
T
 
R 
 
cells constitutively express GlTR (20,
21). Active signaling through GITR to CD25
 
  
 
CD4
 
  
 
T
 
R
 
cells attenuates their suppressive activity, leading to en-
hanced immune responses to self- and nonself antigens
(20). Mere blockade of GITR on T
 
R 
 
cells fails to abrogate
the suppression (20). GITR-ligand (L) is induced on DCs
upon maturation (unpublished data). Thus, GITR–GITR-L
interaction may also contribute to the tuning of CD25
 
 
 
CD4
 
  
 
T
 
R 
 
cell–mediated immunoregulation.
The expression patterns of other accessory molecules on
CD25
 
  
 
CD4
 
  
 
T
 
R 
 
cells are CD45RB
 
low
 
, CD44
 
high
 
, CD5
 
high
 
,
CD54 (intercellular adhesion molecule 1)
 
high
 
, CD11a/
CD18 (LFA-1)
 
high
 
, partly CD62L
 
low 
 
(4). This pattern sug-
gests that they might be in a “primed,” “activated,” “effec-
tor,” or “memory” state probably due to constant stimula-
tion by self-peptides/MHCs on APCs in the normal
internal milieu (4). Upon infection, they can be more
swiftly recruited to the infection site than other T cells as
recently demonstrated by Belkaid et al. (12).
Besides accessory molecules on CD25
 
  
 
CD4
 
  
 
T
 
R 
 
cells,
cytokines also play key roles in tuning their expansion
and activation. High dose IL-2 along with TCR stimula-
tion, for example, triggers their proliferation and neutral-
izes the suppressive activity during their proliferation
(22). Such expanded T
 
R 
 
cells show more potent suppres-
sive activity than before expansion (23). TLR4 stimula-
tion with LPS in the presence of IL-2 also results in their
acquisition of more potent suppressive activity than LPS
stimulation alone (14). It is thus likely that T cell immune
responses to microbes may locally produce a high IL-2
milieu, contributing to the expansion of microbe-specific
T
 
R 
 
cells at the site of infection. Other cytokines may also
participate in the activation or expansion of endogenous
T
 
R 
 
cells (7, 12).
Collectively, these findings indicate that various signals
contribute to the activation and expansion of endogenous
CD25
 
  
 
CD4
 
  
 
T
 
R 
 
cells and thereby to the fine tuning of
the suppressive activity of T
 
R 
 
cells, hence the magnitude
of immune responses. Strong suppression may make theT
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host succumb to the infection whereas weak suppression
may lead to complete eradication of the microbes but may
lose concomitant immunity because of insufficient main-
tenance of memory T cells due to lack of microbe persis-
tence (12). It is therefore required to elucidate how vari-
ous signals, some of which are apparently in opposition
(e.g., signals through CTLA-4 vs. CD28), are integrated
in T
 
R 
 
cells to determine the degree of their expansion and
suppression.
 
Adaptive Nature of CD25
 
  
 
CD4
 
  
 
T
 
R 
 
Cells and Their Roles
in Immunological Diseases.
 
There is now evidence not
only for the presence of CD25
 
  
 
CD4
 
  
 
T
 
R 
 
cells in humans
but also for their essential role in controlling autoimmu-
nity, immunopathology, and allergy in human diseases.
For example, an X-linked recessive autoimmune/inflam-
matory syndrome called IPEX (immune dysregulation,
polyendocrinopathy, enteropathy, X-linked syndrome)
develops autoimmune diseases (such as type 1 diabetes),
inflammatory bowel disease, and allergy similar to those
produced in mice by depletion of CD25
 
  
 
CD4
 
  
 
T
 
R 
 
cells
(24). The causative gene, 
 
Foxp3
 
, which encodes a tran-
scription factor, is specifically expressed in CD25
 
  
 
CD4
 
 
 
T cells in the thymus and periphery. Forced expression of
the 
 
Foxp3
 
 gene in naive T cells converts them to T
 
R 
 
cells
phenotypically and functionally similar to naturally arising
CD25
 
  
 
CD4
 
  
 
TR cells (25). The results indicate that a ge-
netically determined abnormality in the generation or
function of CD25  CD4  TR cells can be a cause of im-
munological disease in humans (Fig. 2). It remains to be
determined how Foxp3, a master regulatory gene for the
development and/or function of CD25  CD4  TR cells,
controls the expression and functions of TR-associated
molecules such as CD25, CTLA-4, GITR, and TLRs. It
is likely that other genetic abnormalities or environmental
insults may also affect CD25  CD4  TR cells and thereby
cause autoimmune and other immunological diseases (26).
Furthermore, defects or polymorphism of other genes en-
coding those molecules (including TLRs) that contribute
to the control of TR cells (see above) may determine the
susceptibility or resistance to autoimmunity, allergy, and
immunopathology.
As discussed above, one important feature of naturally
arising CD25  CD4  TR cells is that they are immunolog-
ically adaptive, i.e., they can expand and augment their
suppressive activity when stimulated through TCR along
with high dose IL-2 or through TLRs (Fig. 1). This
means that repeated microbial infections may not only in-
crease T cell immunity by generating memory T cells but
also strengthen the suppressive activity of endogenous
CD25  CD4  TR cells. Another level of equilibrium set
between the strengthened TR cells and the memory T
cells may ensure effective secondary responses without
damage to the host upon reinfection. Furthermore, con-
sidering that CD25  CD4  TR cells activated by a specific
antigen exert antigen-nonspecific suppression, TR  cells
stimulated by microbial antigens may suppress self-reac-
Figure 1. Signaling to CD25 
CD4   TR  cells via several cell
surface molecules including
TCR, CD28, CTLA-4, GITR,
IL-2 R (CD25), and TLRs re-
sults in augmentation or attenua-
tion of their suppressive activity.
During the proliferation of TR
cells in the presence of high dose
IL-2 along with TCR stimula-
tion, they lose suppressive activ-
ity whereas they show aug-
mented suppressive activity upon
withdrawal of IL-2 after expan-
sion (references 22 and 23). TLR
stimulation may also show a sim-
ilar sequence of events, i.e., loss
of suppressive activity during
proliferation and augmented
suppression after expansion.T
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tive T cells as well in a bystander manner (22, 23). For ex-
ample, inoculation of complete Freund’s adjuvant, which
contains killed tubercle bacilli, inhibits the development
of autoimmune disease in animal models (27, 28). It is
likely in this finding that HSP of tubercle bacilli may acti-
vate endogenous TR cells through stimulating their TLRs,
thereby suppressing self-reactive T cells (29). Other TLR
ligands including endogenous HSPs may also be able to
strengthen the regulatory activity of endogenous TR cells
and prevent autoimmune disease.
Furthermore, assuming that endogenous TR cells play
key roles in preventing autoimmune diseases and allergy in
humans as exemplified in IPEX syndrome, the recent in-
crease of the incidence of autoimmune disease and allergy
in developed countries could be attributed to insufficient
adaptive expansion or strengthening of endogenous TR
cells due to less frequent opportunities for microbial infec-
tions in hygienic societies (26, 30).
Future Perspective. In addition to the control of T cell
activation or nonactivation at the level of APCs that dis-
criminate between “infectious nonself” and “noninfec-
tious self” or sensing “danger” signals (2, 3), TR cells me-
diate another mode of control of the activation and
expansion of aberrant T cells. As shown by Caramalho et
al. (14), CD25   CD4   TR  cells are an evolutionarily
unique T cell subpopulation bearing two kinds of the re-
ceptor: TCRs that recognize a broad repertoire of various
self- and nonself antigens and TLRs that sense conserved
molecular patterns shared by microbial components or
certain endogenous molecules (such as HSPs) released in
inflammation. This dual signaling source for TR cells, to-
gether with other signals via accessory molecules, may en-
able CD25  CD4  TR cells to efficiently and finely tune
their activity to control adaptive immune responses against
self- and nonself antigens (Fig. 2; reference 4). Additional
elucidation of the mechanisms by which endogenous TR
cells are generated, activated, or expanded and those by
which they control other T cells will contribute to our
better control of physiologic and pathologic adaptive im-
mune responses.
The author thanks Z. Fehervari and K.J. Wood for critically read-
ing the manuscript.
Submitted: 6 January 2003
Accepted: 14 January 2003
Figure 2. At least some of CD25  CD4  TR cells are produced by the normal thymus as a functionally mature T cell subpopulation. They specifically
express the Foxp3 gene. Reduction of CD25  CD4  TR cells or attenuation of their suppressive activity by manipulating various molecules shown in Fig.
1 may elicit autoimmunity or enhance autoimmunity, tumor immunity, microbial immunity, or allergy. In contrast, an increase of the number of TR cells
or augmentation of their suppressive activity can delay the rejection of organ grafts and induce transplantation tolerance.T
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